 Lipocine Inc NASDAQ: LPCN has entered into a settlement and license agreement with Clarus Therapeutics to resolve claims in the ongoing intellectual property litigation and interference proceeding. Under the terms of the settlement, both the companies have agreed to dismiss the litigation presently pending in the District Court for the District of Delaware. 